Alicia RodrÃ-guez-GascÃ³n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3925705/publications.pdf

Version: 2024-02-01

51 papers	2,130 citations	304743 22 h-index	233421 45 g-index
52 all docs	52 docs citations	52 times ranked	3202 citing authors

#	Article	IF	Citations
1	Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 143-161.	3.3	488
2	Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. Journal of Infection and Chemotherapy, 2015, 21, 319-329.	1.7	169
3	Augmented Renal Clearance in Critically Ill Patients: A Systematic Review. Clinical Pharmacokinetics, 2018, 57, 1107-1121.	3.5	144
4	Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials, 2020, 10, 364.	4.1	138
5	Applications of lipid nanoparticles in gene therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 109, 184-193.	4.3	88
6	Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: The importance of the entry pathway. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 495-502.	4.3	87
7	Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials, 2016, 90, 40-49.	11.4	81
8	Dextranâ€“protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. International Journal of Pharmaceutics, 2014, 468, 105-111.	5.2	72
9	Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. International Journal of Nanomedicine, 2014, 9, 1833.	6.7	65
10	Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology, 2017, 42, 144-154.	3.0	62
11	Treatment of ocular disorders by gene therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 331-342.	4.3	61
12	Population Pharmacokinetics of Meropenem inÂCritically Ill Patients Undergoing ContinuousÂRenal Replacement Therapy. Clinical Pharmacokinetics, 2008, 47, 173-180.	3.5	56
13	Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 180-189.	3.0	55
14	Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives. BioMed Research International, 2014, 2014, 1-17.	1.9	53
15	The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials. Pharmaceutics, 2021, 13, 833.	4.5	46
16	New gene delivery system based on oligochitosan and solid lipid nanoparticles: â€˜In vitroâ€™ and â€˜in vivoâ€™ evaluation. European Journal of Pharmaceutical Sciences, 2013, 50, 484-491.	4.0	39
17	Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. International Journal of Infectious Diseases, 2020, 93, 329-338.	3.3	36
18	Vaginal gene therapy. Advanced Drug Delivery Reviews, 2015, 92, 71-83.	13.7	32

#	Article	IF	Citations
19	Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA. Molecules, 2020, 25, 5995.	3.8	28
20	Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. Journal of Critical Care, 2019, 50, 69-76.	2.2	27
21	Gene Therapy for Fabry Disease: A Review of the Literature. BioDrugs, 2013, 27, 237-246.	4.6	25
22	Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. International Journal of Pharmaceutics, 2015, 479, 181-188.	5.2	24
23	Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). Colloids and Surfaces B: Biointerfaces, 2016, 146, 808-817.	5.0	23
24	Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis. Experimental Eye Research, 2018, 176, 130-140.	2.6	23
25	Gene delivery in the cornea: in vitro & ex vivo evaluation of solid lipid nanoparticle-based vectors. Nanomedicine, 2018, 13, 1847-1854.	3.3	22
26	Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation. Pharmaceutics, 2020, 12, 54.	4.5	22
27	MMP-9 Downregulation with Lipid Nanoparticles for Inhibiting Corneal Neovascularization by Gene Silencing. Nanomaterials, 2019, 9, 631.	4.1	18
28	Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production. Pharmaceutics, 2020, 12, 584.	4.5	17
29	Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens. International Journal of Antimicrobial Agents, 2015, 45, 504-511.	2.5	16
30	Gene Therapy. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 321-368.	1.1	12
31	Î±-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice. Pharmaceutics, 2021, 13, 771.	4.5	12
32	Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 380-386.	0.5	11
33	mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation. Pharmaceutics, 2021, 13, 1472.	4.5	11
34	Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function. Pharmaceutics, 2021, 13, 1690.	4.5	10
35	Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 626-633.	0.5	9
36	Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 306-311.	0.5	9

#	Article	IF	Citations
37	Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 65-71.	0.5	6
38	Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria. Antibiotics, 2021, 10, 755.	3.7	6
39	Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study. Journal of Intensive Care, 2022, 10, 21.	2.9	6
40	Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of Neisseria gonorrhoeae Infections. Pharmaceutics, 2021, 13, 1699.	4.5	5
41	Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. Pharmaceutics, 2021, 13, 1899.	4.5	5
42	mRNA delivery technologies: Toward clinical translation. International Review of Cell and Molecular Biology, 2022, , 207-293.	3.2	5
43	Quantification of Ceftaroline in Human Plasma Using High-Performance Liquid Chromatography with Ultraviolet Detection: Application to Pharmacokinetic Studies. Pharmaceutics, 2021, 13, 959.	4.5	2
44	Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 306-311.	0.3	1
45	Pharmacokinetic/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2145-2152.	2.9	1
46	Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease. Nanomaterials, 2022, 12, 2339.	4.1	1
47	Development and validation of a LCâ€MS assay for the quantification of ikh12 a novel antiâ€tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study. Biomedical Chromatography, 2015, 29, 1249-1258.	1.7	0
48	Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 626-633.	0.3	0
49	Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 65-71.	0.3	0
50	Nonviral Delivery Systems for Gene Therapy for Retina and Posterior Segment Disease. , 2018, , 131-149.		0
51	Gene-terapia: Ikuspegi terapeutiko berria begietako gaitzen tratamenduan. Ekaia (journal), 2020, , 31-48.	0.0	0